Physician profile
Robin Djang
NPI 1225483183
$2,846.77
in general payments reported to CMS, 2019-2025
32 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $313 · 2023: $358 · 2024: $957 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.94 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $248.02 | 2019-2023 | |
| Immunitybio, INC. | $235.42 | 2024-2025 | |
| Medtronic, INC. | $205.79 | 2025 | Interstim |
| Procept Biorobotics Corporation | $203.01 | 2024 | Aquabeam System |
| Calyxo, INC. | $197.98 | 2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $189.80 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $187.22 | 2023-2025 | Prolaris, Myrisk |
| Cook Medical LLC | $143.18 | 2024 | Litho 150 |
| Novartis Pharmaceuticals Corporation | $136.03 | 2024 | |
| Biotissue Holdings INC. | $129.08 | 2024 | |
| Urovant Sciences INC | $124.95 | 2021 | |
| Merck Sharp & Dohme LLC | $92.59 | 2021 | |
| Edap Technomed INC | $89.10 | 2025 | |
| Profound Medical Corp. | $77.49 | 2023 | Tulsa-Pro |
| Astrazeneca Pharmaceuticals LP | $66.99 | 2023 | Lynparza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $62.62 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $59.68 | 2024 | |
| Ambu INC. | $41.58 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $36.28 | 2025 | Aptra |
| Janssen Scientific Affairs, LLC | $36.04 | 2024 | Erleada |
| Photocure INC | $35.56 | 2024 | Cysview |
| Angiodynamics, INC. | $33.42 | 2024 | Nanoknife |
| Caldera Medical, INC | $28.68 | 2025 | |
| Ethicon US, LLC | $28.49 | 2025 | Echelon Flex |
| Dilon Technologies, INC. | $24.67 | 2025 | Hemoblast Bellows |
| Olympus America INC. | $22.44 | 2025 | Itind System |
| Convatec INC. | $20.19 | 2024 | |
| Telix Pharmaceuticals | $19.57 | 2023 | Illuccix |
| Progenics Pharmaceuticals, INC. | $18.91 | 2025 | |
| Pfizer INC. | $18.59 | 2025 | |
| Accord Healthcare, INC. | $17.23 | 2025 | |
| Antares Pharma, INC. | $16.17 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Djang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.